Loading...
•
Dec 31, 2019
Edwards Lifesciences Q4 2019 Earnings Report
Edwards Lifesciences reported robust fourth quarter performance driven by innovative technologies.
Key Takeaways
Edwards Lifesciences reported a strong fourth quarter with sales growth of 20% to $1.2 billion and adjusted EPS growth of 25% to $1.46. The company's full year sales and earnings significantly exceeded original guidance. 2020 guidance ranges increased: sales $4.6 billion to $5.0 billion; EPS $6.15 to $6.40
Q4 sales grew 20% to $1.2 billion; underlying sales grew 19%
Q4 TAVR sales grew 29%; underlying sales grew 30%
Q4 EPS was $1.32; adjusted EPS grew 25% to $1.46
Full year 2019 sales and earnings significantly exceeded original guidance
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Overall, 2020 sales guidance for Edwards is now expected to be $4.6 to $5.0 billion versus the company’s previous range of $4.5 to $5.0 billion. Additionally, the company now expects full year 2020 adjusted earnings per share of $6.15 to $6.40 versus previous guidance of $6.05 to $6.30. For the first quarter of 2020, the company projects total sales to be between $1.15 and $1.2 billion, and adjusted EPS of $1.49 to $1.59.
Positive Outlook
- 2020 sales guidance for Edwards is now expected to be $4.6 to $5.0 billion
- Full year 2020 adjusted earnings per share of $6.15 to $6.40 is expected
- For the first quarter of 2020, total sales to be between $1.15 and $1.2 billion is projected
- For the first quarter of 2020, adjusted EPS of $1.49 to $1.59 is projected
Revenue & Expenses
Visualization of income flow from segment revenue to net income